Kebin Zheng

Dr. Kebin Zheng


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in American Journal of Translational Research
Verified
Journal Article
Closed access
LGLianting Geng
Lianting Geng
ZBZetong Bai
Zetong Bai
XWXichao Wen
Xichao Wen
HLHaipeng Liu
Haipeng Liu
HXHaipeng Xie
Haipeng Xie
KZKebin Zheng
Kebin Zheng
Objectives: PTEN-Long is a translational variant of phosphatase and tensin homolog (PTEN). This study aimed to assess the effect of PTEN-Long on the biological characteristics of glioma cells and related mechanisms. Methods: A vector stably expressing PTEN-Long was established and transfected into cells, serving as the overexpression group, while a set of empty vectors served as the negative control group. Real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blot were used to detect the expression of PTEN-Long and phosphatidylinositol 3-kinase, Protein kinase B, andnuclear factor-κB (PI3K-AKT-NF-κB). Cell proliferation was assessed with the Cell Counting Kit 8 (CCK8) assay, migration through the scratch test, and invasion by the transwell chamber assay. Cell cycle analysis was performed using flow cytometry. The volume and weight of subcutaneous tumors in nude mice were also evaluated. Results: PTEN-Long expression led to downregulation of p-Akt, NF-κB p65, p-NF-κB p65, and Bcl-xl, and up-regulation of IκBα. In addition, it inhibited glioma cell proliferation, induced cell cycle arrest in the G0/G1 phase, and reduced cell migration and invasion. Moreover, PTEN-Long inhibited the growth of subcutaneous glioma in nude mice. Conclusions: PTEN-Long inhibits the proliferation, migration, and invasion and induces apoptosis in glioma cells by inhibiting PI3K-AKT-NF-κb signaling, implying that PTEN-Long may be a new target for glioma treatment.

15 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HFHongan Fei
Hongan Fei
XWXichao Wen
Xichao Wen
WWWensong Wu
Wensong Wu
HLHaiPeng Liu
HaiPeng Liu
HXHaipeng Xie
Haipeng Xie
ZBZetong Bai
Zetong Bai
Glioblastoma (GBM) is one of the most aggressive brain tumors, and its immunotherapy faces significant challenges, including the physical barrier of the blood-brain barrier, the tumor immunosuppressive microenvironment, and the difficulty of effective immune cell infiltration into tumor tissue. In recent years, the anatomical and functional basis of the meningeal immune system has been gradually revealed, particularly the discovery of the dural lymphatic system and tissue-resident border-associated macrophages (rBAMs), providing new insights for GBM immunotherapy. “Interstitial” immunotherapy, as an innovative strategy, emphasizes a shift from the traditional focus on the tumor interior to the tumor “border,” leveraging the unique advantages of the meningeal immune system to enhance the effectiveness of immune responses. This review systematically examines the current status and dilemmas of GBM immunotherapy, the anatomical and functional basis of meningeal immunity, the discovery and mechanisms of rBAMs, the theoretical implications of “interstitial” immunotherapy, and the clinical translation prospects and challenges of this strategy, aiming to provide new theoretical support and practical guidance for GBM immunotherapy.

21 August 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZBZetong Bai
Zetong Bai
HLHaiguang Liu
Haiguang Liu
YWYan Wang
Yan Wang
HLHaipeng Liu
Haipeng Liu
HXHaipeng Xie
Haipeng Xie
KZKebin Zheng
Kebin Zheng
Glioma, especially glioblastoma multiforme (GBM), has become one of the major clinical challenges in the field of neurooncology due to its high invasiveness and significant multidrug resistance (MDR). The mechanism of drug resistance is complex and involves the synergy of many factors, including the overexpression of MDR related transporters such as P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1) and breast cancer resistance protein (BCRP), the characteristics of tumor stem cells, and the influence of tumor microenvironment (especially hypoxia). In addition, abnormally activated signaling pathways (such as Hippo pathway), abnormal regulation of non coding RNA and mitochondrial dysfunction also contribute to treatment failure. This article reviews the molecular research progress in the mechanism of drug resistance in glioma in recent years, focusing on the dynamic regulation of MDR protein, the drug resistance mediated by tumor stem cells, the impact of tumor microenvironment on drug efficacy, and the role of signaling pathways and non coding RNA in the development of drug resistance. At the same time, this paper also discusses the emerging strategies of drug delivery system and combination therapy based on nanotechnology. Through the systematic integration of existing studies, the aim is to deeply analyze the mechanism of drug resistance, provide theoretical basis and direction for the development of more effective treatment, and ultimately help improve the clinical prognosis.